“Teva won a court case that will allow it to sell a generic version of Bristol’s Baraclude, for hepatitis B, which had $1.4 billion in global sales last year.
A Bristol spokeswoman writes:
The U.S. District Court of the District of Delaware issued an opinion that the composition of matter patent covering the entecavir molecule is invalid as obvious.
We are disappointed in the Court’s decision and believe it is incorrect. We are in the process of reviewing the Court’s decision for the purposes of our appeal and will be evaluating our legal options.
Entecavir is the active ingredient in Baraclude. Baraclude is an antiviral medicine developed as part of Bristol-Myers Squibb’s commitment to improving treatment outcomes for patients with viral hepatitis. Baraclude is approved in the United States to treat patients with chronic hepatitis B in adults who have active virus and liver damage.
How big a deal is this? Not huge, says ISI Group analyst Mark Schoenebaum, who had the first report I saw of the news….”
If you enjoy the content at iBankCoin, please follow us on Twitter
